Wilex Signs Antibody License Agreement With Telix Pharmaceuticals Limited

MELBOURNE (Australia) – 16 January 2017. Telix receives exclusive worldwide rights for the development and commercialization of diagnostic agent REDECTANE^® (INN: ¹²⁴I-Girentuximab)

Telix is delighted to have established this licensing agreement with Wilex for an important product with the potential to significantly impact cancer care.

• Telix receives exclusive worldwide rights for the development and commercialization of diagnostic agent REDECTANE^® (INN: ¹²⁴I-Girentuximab)
• Telix also receives development rights to Girentuximab for use with therapeutic radionuclides, such as ¹⁷⁷Lu (Lutetium)
• Telix is responsible for the manufacturing of Girentuximab for both diagnostic and therapeutic applications
• WILEX to receive upfront payment plus potential clinical and regulatory milestone payments and royalties

The full press release can be found here.